A new simulator can accurately model COVID-19 and the effects of different mitigation strategies, which researchers say could help guide new policies to combat the pandemic.

A new simulator can accurately model COVID-19 and the effects of different mitigation strategies, which researchers say could help guide new policies to combat the pandemic.
Whilst vaccines against COVID-19 show there is light at the end of the tunnel, three main challenges still need to be addressed.
The testing platform identifies the presence of two antibodies in microliter samples of blood.
The results of the company’s COVID-19 vaccine clinical trials are the first to be published in a peer-reviewed journal.
The companies announce the first emergency approval of their mRNA vaccine against COVID-19, with rollout to begin next week.
US company second to report impressive efficacy for its COVID-19 vaccine candidate.
Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study.
New study finds coronaviruses are masters of mimicry, reproducing their host’s immune proteins to remain invisible and help promote infection.
Researchers enhance the immune response against the receptor binding domain of SARS-CoV-2 by presenting it on liposomes, providing a promising strategy for vaccine development targeting this domain.
An inventive new approach lowers the limit of detection for a common assay, allowing researchers to identify elusive biomarkers in complex fluids, like the blood.